defeatHIV Events: Dr. Richard Harrigan to Speak on Management of HIV Drug ResistanceHIV Drug Resistance and the Emerging Role of “Next Generation” DNA Sequencing for Routine Clinical Management of HIV Therapy
Wednesday, October 3, 2012, 3:30pm
Department of Laboratory Medicine Grand Rounds
University of Washington, Health Sciences Bldg, D209
Richard Harrigan, Director, Center for Excellence in HIV/AIDS, University of British Columbia
Dr. Richard Harrigan is the Director of Research Laboratories at the BC Centre for Excellence in HIV/AIDS. His work primarily focuses on HIV drug efficacy, drug resistance, and the human and viral parameters that influence HIV disease progression. At the BC Centre for Excellence in HIV/AIDS, his work has involved investigations using three major cohort studies, as well as the more than five thousand patients in the BC Drug Treatment Program.
Before working at the CfE, Dr. Harrigan was at the pharmaceutical companies Wellcome and Glaxo Wellcome in the United Kingdom. Dr. Harrigan was also one of the first to demonstrate the potential clinical utility of HIV drug resistance testing and introduced one of the world’s first broadly based clinical HIV drug resistance testing programs; this program has tested more than 50,000 clinical samples from across Canada. Dr Harrigan is currently investigating the application of newer “deep-sequencing” technologies in the clinical management of HIV therapies.
Dr. Harrigan holds the Glen-Hillson Professorship in Clinical HIV Virology and the CIHR-GSK Research Chair in HIV/AIDS at the University of British Columbia, and is an Associate Professor in the Division of AIDS (Faculty of Medicine) at the University of British Columbia.